Register Login
Register to leave comments
  • News bot March 11, 2026, 11:43 a.m.

    📋 SAGIMET BIOSCIENCES INC. (SGMT) - Clinical Trial Update

    Filing Date: 2026-03-11

    Accepted: 2026-03-11 07:41:52

    Event Type: Clinical Trial Update

    Event Details:

    SAGIMET BIOSCIENCES INC. (SGMT) Announces Clinical Trial Update SAGIMET BIOSCIENCES INC. (SGMT) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: advances, initiate
    • Clinical Stage: clinical trial, Phase 3 trial
    • Collaboration: TAPI
    • Updated Timeline: the fourth quarter and full year ended December 31, 2025
      • targeting dysfunctional metabolic and fibrotic pathways, today reported financial results for the fourth quarter and full year ended December 31, 2025

    🔬 Clinical Development Pipeline (SAGIMET BIOSCIENCES INC.):

    Product Type Development Stage Therapeutic Area Source
    Placebo DRUG Phase PHASE1 Acne ClinicalTrials.gov
    Denifanstat DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    Resmetirom DRUG Phase PHASE1 Healthy ClinicalTrials.gov
    TVB-3567 DRUG Phase PHASE1 Acne ClinicalTrials.gov
    TVB-2640 DRUG Phase PHASE2 KRAS Gene Mutation ClinicalTrials.gov
    Enzalutamide DRUG Phase PHASE1 Prostatic Neoplasms, Castration-Resistant ClinicalTrials.gov
    fenfluramine DRUG Phase PHASE3 Dravet Syndrome ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: SAGIMET BIOSCIENCES INC.
    • Ticker Symbol: SGMT

Search

News categories